Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Consuelo Buttigliero, Chiara Pisano, Marcello Tucci, Francesca Vignani, Valentina Bertaglia, Davide Iaconis, Pamela Guglielmini, Gianmauro Numico, Giorgio V. Scagliotti & Massimo Di Maio. (2017) Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncologica 56:4, pages 555-562.
Read now
Read now
Pavlos Msaouel, Evanthia Diamanti, Marinela Tzanela & Michael Koutsilieris. (2007) Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opinion on Emerging Drugs 12:2, pages 285-299.
Read now
Read now
Cai Grau, Morten Høyer, Jacob Lindegaard & Jens Overgaard. (2006) The emerging evidence for Stereotactic Body Radiotherapy. Acta Oncologica 45:7, pages 771-774.
Read now
Read now
Bengt Johansson, Mona Ridderheim & Bengt Glimelius. (2005) The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers. Acta Oncologica 44:8, pages 890-895.
Read now
Read now
Seymour Levitt. (2005) Second Acta Oncologia Symposium on Prostate Cancer Controversies. Acta Oncologica 44:6, pages 526-528.
Read now
Read now
Articles from other publishers (31)
Nasreddine El Omari, Saad Bakrim, Asaad Khalid, Ashraf N. Abdalla, Waleed Hassan Almalki, Learn-Han Lee, Chrismawan Ardianto, Long Chiau Ming & Abdelhakim Bouyahya. (2023) Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses. Biomedicine & Pharmacotherapy 164, pages 114886.
Crossref
Crossref
Xiangyu Chen, Qihua Wang, Yang Pan, Shangren Wang, Yuezheng Li, Hao Zhang, Mingming Xu, Hang Zhou & Xiaoqiang Liu. (2023) Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. Frontiers in Endocrinology 14.
Crossref
Crossref
R. Zhong, R. Chu, J. Zhu, J. Ling, L. Zhang, Y. Zhou, M. Yin, Z. Hao, C. Liang, S. Cao, T. Xu, S. Ye & S. Fan. (2023) Research progress on gels-based nanocomposites in the diagnostics and therapy of prostate diseases. Materials Today Sustainability 21, pages 100323.
Crossref
Crossref
Karin Welén & Jan-Erik Damber. (2022) Androgens, aging, and prostate health. Reviews in Endocrine and Metabolic Disorders 23:6, pages 1221-1231.
Crossref
Crossref
Zengshu Xing, Sailian Li, Jiansheng Xing, Gang Yu, Guoren Wang & Zhenxiang Liu. (2022) Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis. Laboratory Investigation 102:6, pages 602-612.
Crossref
Crossref
Xueni Wang, Qian Zhou, Xiaoning Li, Xia Gan, Peng Liu, Xiaotao Feng, Gang Fang & Yonghong Liu. (2022) Insights into Aptamer–Drug Delivery Systems against Prostate Cancer. Molecules 27:11, pages 3446.
Crossref
Crossref
Fan Ge, Zhenyu Huo, Yeling Liu, Xiaoqin Du, Rui Wang, Weiyi Lin, Runchen Wang, Jiana Chen, Yi Lu, Yaokai Wen, Huiying Cao, Siyue Shang, Md Eftekhar & Di Gu. (2022) Association between schizophrenia and prostate cancer risk: Results from a pool of cohort studies and Mendelian randomization analysis. Comprehensive Psychiatry 115, pages 152308.
Crossref
Crossref
Chiara PISANO, Marcello TUCCI, Rosario F. DI STEFANO, Fabio TURCO, Alessandro SAMUELLY, Maristella BUNGARO, Francesca VIGNANI, Federica TARENGHI, Giorgio V. SCAGLIOTTI, Massimo DI MAIO & Consuelo BUTTIGLIERO. (2022) Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva Urology and Nephrology 73:6.
Crossref
Crossref
Gregory J. Nason, Clare O'Connell & Paul K. Hegarty. 2021. Surgical Management of Advanced Pelvic Cancer. Surgical Management of Advanced Pelvic Cancer
214
222
.
Senmao Li, Jindong Sheng, Zhenhua Liu, Yu Fan, Cuijian Zhang, Tianjing Lv, Shuai Hu, Jie Jin, Wei Yu & Yi Song. (2021) Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells. Journal of Cellular and Molecular Medicine 25:5, pages 2436-2449.
Crossref
Crossref
Toshihiko Takeiwa, Yuichi Mitobe, Kazuhiro Ikeda, Kuniko Horie-Inoue & Satoshi Inoue. (2020) Roles of Splicing Factors in Hormone-Related Cancer Progression. International Journal of Molecular Sciences 21:5, pages 1551.
Crossref
Crossref
Ya-nan Man & Yan-fang Chen. (2019) Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. International Urology and Nephrology 51:12, pages 2189-2199.
Crossref
Crossref
Catalina Asencio-Barría, Norah Defamie, Juan C. Sáez, Marc Mesnil & Alejandro S. Godoy. (2019) Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer. Cancers 11:9, pages 1370.
Crossref
Crossref
Ruixiao Lu, Rui Tang & Jing Huang. 2019. Statistical Methods in Biomarker and Early Clinical Development. Statistical Methods in Biomarker and Early Clinical Development
137
166
.
Sergio Rizzo, Antonio Galvano, Francesco Pantano, Michele Iuliani, Bruno Vincenzi, Francesco Passiglia, Silvia Spoto, Giuseppe Tonini, Viviana Bazan, Antonio Russo & Daniele Santini. (2017) The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. Critical Reviews in Oncology/Hematology 120, pages 227-233.
Crossref
Crossref
Senmao Li, Chenghe Wang, Xiao Yu, Huanlei Wu, Jia Hu, Shaogang Wang & Zhangqun Ye. (2017) miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression. Oncology Reports 37:1, pages 241-248.
Crossref
Crossref
Pasquale Rescigno, David Lorente, Diletta Bianchini, Roberta Ferraldeschi, Michael P. Kolinsky, Spyridon Sideris, Zafeiris Zafeiriou, Semini Sumanasuriya, Alan D. Smith, Niven Mehra, Anuradha Jayaram, Raquel Perez-Lopez, Joaquin Mateo, Chris Parker, David P. Dearnaley, Nina Tunariu, Alison Reid, Gerhardt Attard & Johann S. de Bono. (2016) Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology 70:5, pages 724-731.
Crossref
Crossref
Francesco Pantano, Giulia Ribelli, Michele Iuliani, Marco Fioramonti, Mark Leakos, Alice Zoccoli, Daniele Santini, Giovanni Muto & Giuseppe Tonini. (2016) New Molecular Targets in Metastatic Prostate Cancer. Journal of Cancer Therapy 07:06, pages 388-401.
Crossref
Crossref
Paul Cathcart, Walter Lucchesi, Silvia Ottaviani, Alex De Giorgio, Jonathan Krell, Justin Stebbing & Leandro Castellano. (2015) Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Practice & Research Clinical Endocrinology & Metabolism 29:4, pages 529-543.
Crossref
Crossref
Greg N. Brooke, Simon C. Gamble, Michael A. Hough, Shajna Begum, D. Alwyn Dart, Michael Odontiadis, Sue M. Powell, Flavia M. Fioretti, Rosie A. Bryan, Jonathan Waxman, Robin Wait & Charlotte L. Bevan. (2015) Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells*. Molecular & Cellular Proteomics 14:5, pages 1201-1216.
Crossref
Crossref
Marcello Tucci, Giorgio Vittorio Scagliotti & Francesca Vignani. (2015) Metastatic castration-resistant prostate cancer: time for innovation. Future Oncology 11:1, pages 91-106.
Crossref
Crossref
Go J. Yoshida & Hideyuki Saya. (2014) EpCAM expression in the prostate cancer makes the difference in the response to growth factors. Biochemical and Biophysical Research Communications 443:1, pages 239-245.
Crossref
Crossref
Byung Kuk Kwak & Sung-Ho Lee. (2013) Intratesticular Injection of Hypertonic Saline : Non-Invasive Alternative Method for Animal Castration Model. Development & Reproduciton 17:4, pages 435-440.
Crossref
Crossref
N D Shore, P-A Abrahamsson, J Anderson, E D Crawford & P Lange. (2012) New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer and Prostatic Diseases 16:1, pages 7-15.
Crossref
Crossref
C. L. Goh, F. R. Schumacher, D. Easton, K. Muir, B. Henderson, Z. Kote‐Jarai & R. A. Eeles. (2012) Genetic variants associated with predisposition to prostate cancer and potential clinical implications. Journal of Internal Medicine 271:4, pages 353-365.
Crossref
Crossref
Eleni V. Pappa, Aikaterini A. Zompra, Zinovia Spyranti, Zoi Diamantopoulou, George Pairas, Fotini N. Lamari, Panagiotis Katsoris, Georgios A. Spyroulias & Paul Cordopatis. (2011) Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs. Biopolymers 96:3, pages 260-272.
Crossref
Crossref
M Tucci, A Mosca, G Lamanna, F Porpiglia, M Terzolo, F Vana, C Cracco, L Russo, G Gorzegno, M Tampellini, M Torta, G Reimondo, M Poggio, R M Scarpa, A Angeli, L Dogliotti & A Berruti. (2008) Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer and Prostatic Diseases 12:1, pages 94-99.
Crossref
Crossref
H.F. L’Eplattenier, B. Klem, E. Teske, F.J. van Sluijs, S.A. van Nimwegen & J. Kirpensteijn. (2008) Preliminary results of intraoperative photodynamic therapy with 5-aminolevulinic acid in dogs with prostate carcinoma. The Veterinary Journal 178:2, pages 202-207.
Crossref
Crossref
Inbal Boger-Megiddo, Noel S. Weiss, Matt J. Barnett, Gary E. Goodman & Chu Chen. (2008)
V89L Polymorphism of the 5α-Reductase Type II Gene (
SRD5A2
), Endogenous Sex Hormones, and Prostate Cancer Risk
. Cancer Epidemiology, Biomarkers & Prevention 17:2, pages 286-291.
Crossref
Crossref
Alexander Kutikov, Thomas J. Guzzo & S. Bruce Malkowicz. (2006) Clinical Approach to the Prostate: An Update. Radiologic Clinics of North America 44:5, pages 649-663.
Crossref
Crossref
P W HarveyD J Everett & C J Springall. (2016) Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Human & Experimental Toxicology 25:7, pages 395-404.
Crossref
Crossref